This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.
This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.
A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.
In a population derived from 14 TIMI clinical trials, CV events caused the majority of deaths post-NSTE-ACS, with recurrent MI representing the most common cause of death within the first 30 days, and sudden death after the first 30 days.
A Mendelian randomization study combined with metabolic biomarker analysis shows that CETP is an important causal determinant of HDL and VLDL concentration and composition.
The phase 3a PIONEER 6 trial met its primary endpoint, showing non-inferiority with regard to MACE, which was driven by a significant reduction in CV and all-cause mortality, compared to placebo, on top of standard care in T2DM.
In diabetic patients at high cardio-renal risk, linagliptin was non-inferior to placebo in preventing CV outcomes, but led to slightly more renal outcomes compared with placebo.
AHA 2018 In PEGASUS-TIMI 54, a patient selection strategy identified a subgroup of patients who may benefit more from long-term treatment with ticagrelor and aspirin, with lower bleeding risk.
In an observational study, antihypertensive treatment was not associated with reduced mortality or rates of CVD in low-risk patients with mild hypertension.
The ODYSSEY OUTCOMES trial met its primary safety endpoint, showing reduced risk of MACE with alirocumab in patients with ACS compared to placebo, which is dependent on baseline LDL-c levels.
In a large cohort study, pulse pressure stress index (P2SI) was inversely associated with risk of HF and all-cause mortality in individuals with suspected CAD.